News

Novartis group Sandoz has acquired rights to Pfizer’s PF-06438179, a biosimilar of MSD’s Remicade (infliximab), in the 28 countries that form the European Economic Area (EEA), further strengthening its immunology offering.

GlaxoSmithKline and a number of other pharmaceutical companies have been fined £45 million by the UK’s Competition and Markets Authority for anti-competitive conduct relating to the supply of the antidepressant Seroxat (paroxetine).

As expected, Health Secretary Jeremy Hunt has announced that a new contract will be imposed on junior doctors from August 1, after years of negations failed to reach a resolution.

It is looking likely that government will impose a new working contract for junior doctors after being advised by its lead negotiator Sir David Dalton that there is no realistic prospect of a deal.

Generic drugs giant Mylan is acquiring Swedish drugmaker Meda in a cash and stock deal valued at around $9.9 billion.

A new initiative striving to boost London’s position as a global centre for the uptake and commercialisation of pioneering digital health technologies has had its official launch in London this week.

Hikma Pharmaceuticals has dropped the cash portion of its offer for Boehringer Ingelheim’s US generics unit Roxane Laboratories by some $535 million, after due diligence revealed much lower than expected revenue performance and forecasts.

Dublin, Ireland-based Alkermes has kicked off a second Phase III trail of its investigational antipsychotic ALKS 3831, testing the drug’s effect on weight against that of olanzapine (Lilly’s Zyprexa).

PharmaTimes Media invites you to join them in Atlanta on the 17 April 2016 for a celebration of excellence in clinical research.

The level of engagement in the 2016 International Clinical Researcher of the Year competition has been fantastic, with entrants hailing from 48 different countries across the globe.

The US Food and Drug Administration’s Arthritis Advisory Committee is backing the approval of Pfizer and Celltrion’s CT-P13, a biosimilar to Janssen Biotech’s blockbuster Remicade. 

Merck & Co has filed a Biologics License Application in the US for its investigational, ALK-partnered* house dust mite pill.

With no signs of a resolution anytime soon, junior doctors in England have once again taken to picket lines across the country in protest against working and pay conditions being proposed by the government.

The Royal College of Paediatrics and Child Health (RCPCH) has launched a new fund to help boost the number of child health researchers on home shores and abroad and thus “safeguard the future health of the nation”. 

Phasing out unacceptable long-distance admissions for severely mentally ill patients and quicker access to acute psychiatric care are two key recommendations made by an Independent Commission for improving services in England.